Brain Health & Nootropics
Route(s)
Subcutaneous
Typical dose
100 mcg
Dosing window
Pre-Bed
Receptor / target
Delta Sleep Pathways
Properties
Not listed
Pre-mixed
No
DSIP (Delta Sleep-Inducing Peptide)
← Back to Library
Protocol not independently verified FDA safety flag Circadian Neural
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or human-trial protocol above.
Compound Profile
DSIP (Delta Sleep-Inducing Peptide) is reviewed here for cognition, mood, and brain-health context.
Research Summary
Evidence Strength
Very limited
Primary Evidence
Safety notices, literature searches, limited protocol data
Research Focus
Cognition, Mood, Brain health
Mechanism
Target context: Delta Sleep Pathways
Long-Term Data
Limited, unclear, or affected by safety flags.
Current Consensus
Claims need extra caution because evidence is thin or safety flags apply.
Route(s)
Subcutaneous
Typical dose
100 mcg
Dosing window
Pre-Bed
Receptor / target
Delta Sleep Pathways
Properties
Not listed
Pre-mixed
No
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 100 mcg | Administer 30-60 minutes before bedtime. |
| Week 2 | 150 mcg | Administer 30-60 minutes before bedtime. |
| Week 3 | 200 mcg | Administer 30-60 minutes before bedtime. |
| Weeks 4-8 | 250-300 mcg | Administer 30-60 minutes before bedtime. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Alternative: Jet Lag / Circadian Reset
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-2 | 200mcg | Used strictly for 1-2 nights following severe time zone changes. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative 2: 12-Week Escalation
| Timeframe | Dose | Notes |
|---|---|---|
| Week 1 | 100mcg 1x Daily | Take dose 30 mins: 1 hour before bedtime. |
| Week 2 | 200mcg 1x Daily | Take dose 30 mins: 1 hour before bedtime. |
| Week 3 | 300mcg 1x Daily | Take dose 30 mins: 1 hour before bedtime. |
| Week 4 | 400mcg 1x Daily | Take dose 30 mins: 1 hour before bedtime. |
| Week 5 | 500mcg 1x Daily | Take dose 30 mins: 1 hour before bedtime. |
| Week 6 | 600mcg 1x Daily | Take dose 30 mins: 1 hour before bedtime. |
| Week 7-12 | 700mcg 1x Daily | Take dose 30 mins: 1 hour before bedtime. |
Alternative research-context example; not an approved-label regimen unless marked above.
Protocol logic check
Protocol context: Nootropic protocols are state-dependent: sleep, anxiety, stimulants, psychiatric history, and route can change the response. The logic is morning-biased, low-entry dosing, and stopping if arousal or mood destabilizes. Entry context: target (Delta Sleep Pathways); route Subcutaneous; timing Pre-Bed. Unapproved or unverified dosing examples are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit.
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | FDA safety-risk context or unapproved compounded-use warning is attached to this entry; no FDA-approved human label was identified for this compound/page context. |
|---|---|
| Where studied | Studied in neuroprotection, cognition, anxiety, sleep, stroke, neuropathy, or neuropeptide models depending on the target and route. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records |
| Target and route context | Target/receptor: Delta Sleep Pathways. Route(s): Subcutaneous. Dosing window on page: Pre-Bed. |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: FDA safety-risk context plus missing approved-label dosing; published mechanisms do not remove compounding, purity, sterility, or human-safety uncertainty. |
Source-linked findings
- Nootropic and neuropeptide claims need separation between animal neuroprotection, regional clinical literature, and modern randomized human trials.
- Sleep, anxiety, psychiatric history, blood pressure, and route-specific delivery are common practical limits.
- FDA lists emideltide/DSIP among withdrawn nominated bulk substances with insufficient route-specific safety information.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Week 1, 100 mcg; Alternative: Jet Lag / Circadian Reset: Days 1-2, 200mcg.
- Key limitation: FDA safety-risk context plus missing approved-label dosing; published mechanisms do not remove compounding, purity, sterility, or human-safety uncertainty.
- Monitor sleep, anxiety or mood activation, blood pressure, seizure history, psychiatric history, and route-specific nasal or injection irritation.
Selected medical sources
Independent evidence
Independent safety notes: FDA lists emideltide/DSIP among withdrawn nominated bulk substances with insufficient route-specific safety information.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Narcolepsy: DSIP drives delta sleep-state induction in thalamocortical circuits; in subjects with narcolepsy, which is characterized by dysregulated and abrupt sleep-state transitions (REM intrusions, cataplexy, sleep paralysis), exogenous delta sleep promotion may further destabilize the already-fragile boundary between sleep and wake states.
- Severe major depressive disorder with psychomotor retardation: the altered NREM/REM sleep architecture characteristic of severe depression (shortened REM latency, reduced slow-wave sleep proportion) may respond unpredictably to exogenous DSIP; artificially deepening delta sleep without addressing the underlying HPA axis dysregulation and monoamine depletion could worsen the condition.
- Known hypersensitivity to DSIP or peptide excipients.
- Daytime or non-pre-bed administration: DSIP must be administered within the pre-sleep behavioral window (30-60 minutes before intended sleep onset); administration at any other time of day produces inappropriate drowsiness, circadian disruption, and loss of the specific thalamocortical sleep-induction mechanism.
- Operating heavy machinery, driving, or any safety-critical activity within 4-6 hours of DSIP administration: the delta sleep-inducing effect creates significant drowsiness; subjects must be in a position to sleep following administration.
- Concurrent use with CNS depressants (benzodiazepines, z-drugs, opioids, barbiturates, alcohol): additive CNS depression; the combined sedative effect could produce dangerous respiratory depression and excessive sedation.
- Pregnancy: no safety data; neuromodulatory peptide effects on fetal thalamic and hypothalamic development are not characterized.
- Breastfeeding: no safety data.
- Pediatric use: sleep architecture differs substantially in children and adolescents; safety not established.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Next-day grogginess and lethargy: the most commonly reported adverse effect; dose-dependent; excessive delta sleep induction extends into early morning hours producing post-sleep inertia; most pronounced when doses exceed individual threshold (typically >400mcg); managed by starting at 100mcg and escalating slowly.
- Excessive sedation within the dosing window: if DSIP takes effect before the subject has completed necessary pre-bed activities; the 30-60 minute administration window is a precise recommendation and should be treated as one.
- Unusual dreams or altered dream content: delta sleep promotion alters the REM/NREM cycle architecture; the subsequent REM rebound that follows deep NREM may produce more vivid or intense dreaming in some subjects.
- Morning hypotension and dizziness on standing: sluggish autonomic recovery from deep delta sleep in some subjects; drink water before standing; do not stand abruptly.
- Mild headache on waking: uncommon; possibly related to the altered neurovascular tone during deep sleep or glymphatic activity changes.
- Rebound insomnia on cessation: mild; not a withdrawal syndrome in the pharmacological sense but a functional consequence of DSIP-habituated sleep architecture adjusting back to baseline; typically resolves within 1-3 nights.
- HPA axis modulation: DSIP has documented effects on corticosterone and LH pulsatility; at high doses, chronic use may produce subclinical changes in cortisol awakening response or LH pulse amplitude; monitor in subjects with pre-existing endocrine conditions.
- Tolerance development with continuous long-term use: the mechanistic basis for the 8-12 week cycle limit and 4-8 week washout; continuous exposure reduces the sleep-promoting response as receptor systems adapt.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.